Journal article
Combination Therapy for Mycoplasma genitalium, and New Insights Into the Utility of parC Mutant Detection to Improve Cure
LA Vodstrcil, EL Plummer, M Doyle, GL Murray, K Bodiyabadu, JS Jensen, D Whiley, E Sweeney, DA Williamson, EPF Chow, CK Fairley, CS Bradshaw
Clinical Infectious Diseases | Published : 2022
DOI: 10.1093/cid/ciab1058
Abstract
Background: Mycoplasma genitalium (MG) infection is challenging to cure because of rising antimicrobial resistance and limited treatment options. Methods: This was a prospective evaluation of the efficacy and tolerability of resistance-guided combination antimicrobial therapy for MG treatment at Melbourne Sexual Health Centre (August 2019-December 2020). All patients received 7 days of doxycycline before combination therapy based on the macrolide-resistant profile. Macrolide-susceptible infections received combination doxycycline + azithromycin (1 g, day 1; 500 mg, days 2-4) and macrolide-resistant infections combination doxycycline + moxifloxacin (400 mg daily for 7 days). Adherence and adv..
View full abstractRelated Projects (2)
Grants
Awarded by Australian NHMRC Leadership Investigator Grants
Awarded by Australian NHMRC Emerging Leadership Investigator Grants
Awarded by Australian Research Council (ARC) Industrial Transformation Research Hub Grant
Funding Acknowledgements
C. K. F. and C. S. B. are supported by Australian NHMRC Leadership Investigator Grants (GNT1172900, and GNT1173361, respectively). E. P. F. C. and D. W. are supported by Australian NHMRC Emerging Leadership Investigator Grants (GNT1172873 and GNT1174555, respectively) This work was also supported by an Australian Research Council (ARC) Industrial Transformation Research Hub Grant (IH190100021, C. S. B., L. A. V., G. L. M., D. W., E. S., D. A. W.) and Victorian Medical Research Acceleration Fund grant (G. L. M., C. S. B.). D. M. W. is supported by a Queensland Advancing Clinical Research Fellowship from the Queensland Government. C. S. B reports that over the past 15 years MSHC has received funding to support research nurse salary time to support independent investigator led research on Mycoplasma genitalium from Speedx Pty Ltd, and has received diagnostic kits and diagnostic platforms from Speedx Pty ltd, Hologic Pty Ltd, and Cepheid Pty Ltd; C. S. B. has advised a number of industries over the years including Nabriva, GSK, and Roche Pty Ltd but has not received payment for this advisory role; C. S. B. is on the board of the International Society for STD Research (ISSTDR). J. S. J. reports honoraria for educational activities from the following (all to J. S. J.): SpeeDx, Hologic, and Cepheid; reports travel support from the following (all to J. S. J.): Hologic and Cepheid; reports participation on DSMB/advisory board for the following (all payments to J. S. J.): Cepheid, Abbott, Roche, Nabriva, and GSK; served in the following unpaid leadership roles: National representative, IUSTI Europe; European STI Guidelines Editorial Board; ESCMID Study Group for Mycoplasma and Chlamydia Infections-ESGMAC, Scientific Officer; reports funding, provision of study materials, travel support to institution, speakers fee (paid to J. S. J.), from Hologic; reports the following other interest: SpeeDx Contract work to SSI; GSK Contract work to SSI; Nabriva Contract work to SSI. D. W. reports support from the following (paid to their institution): SpeeDx Pty Ltd, ARC, and Qld government. G. L. M. reports Victorian Medical Research Acceleration Fund grant, funds were paid to support research activities from Department of Health and Human Services, State Government of Victoria, Australia and Industrial Transformation Research Hub grant, funds were paid to support research activities from The Australian Research Council, both during the conduct of the study; reports research agreement for diagnostic method study, donation of kits to study from TIB-MOLBIOL, outside the submitted work.